

CURRICULUM VITAE

May 1, 2017

NAME:

DAMIAN A. LABER, M.D., F.A.C.P.

CURRENT POSITIONS:

Senior Member, Tenured
Head Section of Satellite Oncology
Moffitt Cancer Center

Professor of Medicine and Oncologic Sciences
Director Division of Hematology/Oncology
University of South Florida

ADDRESS INFORMATION:

Moffitt Cancer Center at TGH
Tampa General Hospital Cancer Center
3 Tampa General Circle
Tampa, FL 33606

Division of Hematology/Oncology
USF Morsani College of Medicine
13220 USF Laurel Drive, MDF 4149
Tampa, FL 33612

TELEPHONE AND EMAIL:

Mobile 813-774-1464
USF office 813-974-372
TGH clinic 813-844-7585/3952
damian.laber@gmail.com

DATE & PLACE OF BIRTH:

28th February 1968
Buenos Aires, Argentina

CITIZENSHIP:

United States of America

SEX:

Male

CONTINUED

EDUCATION:

UNDERGRADUATE EDUCATION AND HIGH SCHOOL:

Colegio Nacional de Buenos Aires Buenos Aires, Argentina	Bachelor in Sciences	1981-1986
---	----------------------	-----------

POSTGRADUATE EDUCATION:

University of Buenos Aires Buenos Aires, Argentina	M.D.	3/1987-1/1992
---	------	---------------

POSTGRADUATE PROFESSIONAL TRAINING:

Huron Hospital Cleveland Clinic Health System, Cleveland, Ohio	Intern in Internal Medicine	7/1994-6/1995
---	-----------------------------	---------------

Huron Hospital Cleveland Clinic Health System, Cleveland, Ohio	Resident in Internal Medicine	7/1995-6/1997
---	-------------------------------	---------------

Hillcrest & Southpointe Hospital Cleveland Clinic Health System, Cleveland, Ohio	Chief Resident	6-12/1996
---	----------------	-----------

Fred Hutchinson Cancer Research Center Seattle, Washington	Bone Marrow Transplant Resident	11/1995
---	---------------------------------	---------

Baylor College of Medicine Houston, Texas	Fellow in Hematology/Oncology	7/1997-6/2000
--	-------------------------------	---------------

U.T. M.D Anderson Cancer Center Houston, Texas	Fellow in Hematology/Oncology	9/1998-2/1999
---	-------------------------------	---------------

CONTINUED

ACADEMIC AND PROFESSIONAL EXPERIENCE:

ACADEMIC APPOINTMENTS:

Senior Member	Moffitt Cancer Center Tampa, Florida	2014-current
Head Section of Satellite Oncology	Moffitt Cancer Center Tampa, Florida	2014-current
Professor of Oncologic Sciences	University of South Florida Tampa, Florida	2014-current
Professor of Medicine	University of South Florida Tampa, Florida	2013-current
Director of the Division of Hematology and Medical Oncology	University of South Florida Tampa, Florida	2013-current
Professor of Medicine (endowed) Gussman Chair in Internal Medicine	The University of Oklahoma Tulsa, Oklahoma	2010-2012
Director of the OU Tulsa Cancer Center	The University of Oklahoma Tulsa, Oklahoma	2010- 2012
Chief of the Section of Hematology and Medical Oncology	The University of Oklahoma Tulsa, Oklahoma	2010- 2012
Associate Professor of Medicine (Tenured)	University of Louisville Louisville, Kentucky	2007-2010
Scientist	James Graham Brown Cancer Center Louisville, Kentucky	2001-2010
Director, Genitourinary Cancer Clinical Research Program	University of Louisville James Graham Brown Cancer Center Louisville, Kentucky	2001-2010

CONTINUED

Director, Hematology and Medical Oncology Fellowship Program	University of Louisville James Graham Brown Cancer Center Louisville, Kentucky	2001-2010
Associate Faculty, Clinical Research, Epidemiology and Statistics Training Program (CREST)	University of Louisville School of Public Health and Information Sciences Louisville, Kentucky	2003-2010
Assistant Professor of Medicine	University of Louisville Louisville, Kentucky	2001-2006

HOSPITAL APPOINTMENTS:

Staff Physician	Tampa General Hospital Tampa, Florida	2013-current
Staff Physician	Hillcrest Medical Center Tulsa, Oklahoma	2010-2012
Staff Physician	Saint Francis Hospital Tulsa, Oklahoma	2010-2012
Staff Physician	St. John Medical Center Tulsa, Oklahoma	2010-2012
Staff Physician	University of Louisville Hospital Louisville, Kentucky	2001-2010
Staff Physician	Norton Hospital Louisville, Kentucky	2001-2010
Staff Physician	Jewish Hospital Louisville, Kentucky	2001-2010
Staff Physician	Veterans Affairs Medical Center Louisville, Kentucky	2001-2010

CONTINUED

Staff Physician	Taylor Regional Hospital Campbesville, Kentucky	2001-2008
-----------------	--	-----------

TEACHING:

SELECTED EDUCATIONAL ACTIVITIES:

Lecturer, Hematology/Oncology Fellowship Core Curriculum Moffitt Cancer Center, University of South Florida	2013-current
Lecturer, Internal Medicine Lecture Series Department of Medicine, University of South Florida	2013-current
Lecturer, Leadership Enhancement and Development Medicine International, University of South Florida	2015-current
Faculty Leader, Community Medicine Academy The University of Oklahoma, School of Community Medicine	2010-2012
Faculty and Mentor, Internal Medicine Residency Program The University of Oklahoma, Tulsa	2010-2012
Faculty, Summer Institute The University of Oklahoma, School of Community Medicine	2010-2012
Director of the Hematology and Medical Oncology Fellowship Program University of Louisville, Louisville, KY	2001-2010
Faculty, PHCI 626 Clinical Trials III: Practicum in Clinical Trials Clinical Research, Epidemiology and Statistics Training (CREST) Program National Institutes of Health Clinical Research Curriculum Award (K30) School of Public Health and Information Sciences, University of Louisville	2003-2010
Faculty, BIOC-675/875 Cancer Biology Course Graduate Program, Department of Molecular Biology, University of Louisville	2005-2010
Organizer and moderator of the Writing Club J. G. Brown Cancer Center, University of Louisville	2004-2010

CONTINUED

Damian A. Laber, M.D., F.A.C.P.

Page 6

Moderator, Hematology Grand Rounds J. G. Brown Cancer Center, University of Louisville	2001-2010
Moderator, Multi-Modality Conference J. G. Brown Cancer Center, University of Louisville	2001-2010
Moderator, Tumor Conference J. G. Brown Cancer Center, University of Louisville	2001-2010
Organizer, moderator and presenter of the Fellows Conference J. G. Brown Cancer Center, University of Louisville	2001-2010
Lecturer, Internal Medicine Lecture Series Department of Medicine, University of Louisville	2001-2010
Lecturer, Primary Care Clerkship—Integrated Lecture Series School of Medicine, University of Louisville	2001-2010
Course Director, 2007 Annual Louisville Update in Oncology, ASCO Review Galt House East, Louisville, KY	9/08/2007
Course Director, Second Annual Louisville Update in Oncology, ASCO Review The Marriott Hotel, Louisville, KY	7/15/2006
Course Director, Second Annual Louisville Update in Hematology The Marriott Hotel, Louisville, KY	2/26/2005
Course Director, First Annual Louisville Update in Oncology, ASCO Review The Camberley Brown Hotel, Louisville, KY	2/04/2006
Faculty, Progress in the Treatment of Colorectal Cancer Norton Hospital, Louisville, KY	3/19/2005
Course Director, First Annual Louisville Update in Hematology The Camberley Brown Hotel, Louisville, KY	2/26/2005
Organizer and moderator of the Oncology Clinical Trials Conference J. G. Brown Cancer Center, University of Louisville	2003-2004

CONTINUED

Organizer and moderator of the Genitourinary Tumor Board J. G. Brown Cancer Center, University of Louisville	2002-2003
Organizer and moderator of the Cancer Genetics Program J. G. Brown Cancer Center, University of Louisville	2001-2002
Moderator, organizer and coordinator of the Fellows Journal Club Baylor College of Medicine, Houston, Texas	1998-2000
Moderator and presenter at the “International visiting physician educational program: The contemporary management of the patient with breast cancer” Baylor College of Medicine, Houston, Texas	11/10/1999
Moderator and presenter at the “International visiting physician educational program: The contemporary management of the patient with breast cancer” Baylor College of Medicine, Houston, Texas	10/15/1999
Moderator and presenter at “ASCO Update” Houston, Texas	7/14/1999
Moderator and presenter “Combined Modality Therapy for Stage III NSCLC” Houston, Texas	2/23/1999
Moderator of the Multi-disciplinary Oncology Tumor Board Ben Taub General Hospital, Houston, Texas	1998

MENTORING

Michael Jaglal, MD Faculty	Moffitt Cancer Center	2014-current
Ankita Patel, MD Faculty	Moffitt Cancer Center	2014-current
Daniel Ross Medical Student	University of South Florida	2013-current

MENTOR - INSTRUCTOR OF VISITING SCHOLARS

Wu Chongyang, Associate Chief Physician Oncology, Oncology Department Second Hospital of Lanzhou University	2016
--	------

CONTINUED

Wei Yan, Director Oncology, Oncology Department Guigang City People's Hospital	2016
Zhou Shaozhang, Deputy Chief Oncology, Second Department of Chemotherapy Tumor Hospital Of Guangxi Zhuang Autonomous Region	2016
Zhihui Liu, MD, Deputy Chief Physician, Chemotherapy Department The Affiliated Tumor Hospital of Guangxi Medical University	2015

MENTOR HEMATOLOGY AND MEDICAL ONCOLOGY FELLOWS

Blakely D. Kute, MD	2010
Alireza Abdolmohammadi, M.D.	2010
Fatima S. Raza, M.D.	2010
Nagendra Natarajan, M.D.	2009-2010
Cesar Rodriguez-Valdez, M.D.	2009-2010
Raul Storey, M.D.	2009-2010
Michael Driscoll, M.D.	2008-2010
Wenqing Zhang, M.D., Ph.D.	2008-2010
Dong Xiang, M.D., Ph.D.	2008-2010
Mohamad Janjua, M.D.	2007-2010
Fadi Kayali, M.D.	2007-2010
Amir Harandi, M.D.	2006-2009
Gullierme Rabinowits, M.D.	2006-2009
Arash Rezazedah, M.D.	2006-2009
M. Iltaf Khan, M.D., Ph.D.	2005-2008
Mian Mushtaq, M.D.	2005-2008
Padmini Moffett, M.D.	2005-2008
Wangjiang Zhong, M.D., Ph.D.	2005-2008
Carlos Arce-Lara, M.D.	2004-2005
Stephanie Wagner, M.D.	2004-2007
Monte E. Martin, M.D.	2004-2007
Fadi Hayek, M.D.	2003-2006
Stephen Makoni, M.D.	2003-2006
Simeon Jaggernauth, M.D.	2003-2005
Ifeoma Roseline Okeke, M.D.	2003-2005
Muneeb A. Choudry, M.D.	2002-2005
Yi Feng, M.D., Ph.D.	2001-2004
Carolina Salvador, M.D.	2001-2004
Yasonda Devabhaktuni, M.D.	2001-2004

CONTINUED

Damian A. Laber, M.D., F.A.C.P.
Page 9

Goetz H. Kloecker, M.D., MSPH	2001-2004
Apurva C. Mehta, M.D.	2002-2003
Dilawar Khan, M.D.	2000-2003
Mary Li, M.D., Ph.D.	2000-2002

MEDICAL LICENSURES:

Florida State	2013-Present
Indiana State	1999-Present
Drug Enforcement Administration (DEA)	2000-Present

BOARD CERTIFICATIONS:

Diplomate, American Board of Internal Medicine (Re-certified in 2008)	1997-2018
Diplomate, ABIM Subspecialty Hematology (Re-certified in 2010)	2000-2020
Diplomate, ABIM Subspecialty Medical Oncology (Re-certified 2011)	2001-2021

PROFESSIONAL SOCIETIES:

American Society of Clinical Oncology	1999-Present
American Society of Hematology	2002-Present
American College of Physicians (Fellow 2005)	1994-Present
American Society of Internal Medicine	1994-Present
European Hematology Association	2006-Present
Greater Louisville Medical Society, Kentucky	2001-2012
American Medical Association	2001-2012
Southwest Oncology Group	2001-2010

EDITORIAL BOARDS, ADVISORY COUNCILS AND COMMITTEES - SERVICE

EDITORIAL BOARD:

Journal of Cancer Prevention & Current Research	Editor	2014-current
Cancer Control Journal	Reviewer	2014-current

CONTINUED

Indian Journal of Medical Research	Reviewer	2016
Chemotherapy	Reviewer	2008
The Journal of Urology	Reviewer	2007
Southern Medical Journal	Reviewer	2007
Annals of Internal Medicine	Reviewer	2006
Thrombosis and Haemostasis	Reviewer	2005
Canadian Medical Association Journal	Reviewer	2005
Archives of Internal Medicine	Reviewer	2004
Archives of Pathology	Reviewer	2004
ABIM Subspecialty Oncology	Reviewer	2001
ABIM Subspecialty Hematology	Reviewer	2001
Bone Marrow Transplantation	Reviewer	2000

COMMITTEES:

Member, Cancer Committee Tampa General Hospital, Tampa, FL	2013-current
Member, Oncology Service Line Tampa General Hospital, Tampa, FL	2013-current
Member, Internal Medicine Division Directors Committee University of South Florida, Tampa, FL	2013-current
Chairman, OU Tulsa Cancer Center Committee University of Oklahoma, Tulsa, OK	2010-2012
Member, Utilization Management Committee University of Louisville Hospital, Louisville, KY	2009-2010
Member, Radiation Oncology Chairman Search Committee University of Louisville, Louisville, KY	2008-2010
Member, Anatomic Pathology Chief Search Committee University of Louisville, Louisville, KY	2008-2010
Member, Data & Safety Monitoring Board J. G. Brown Cancer Center, University of Louisville	2006-2010

CONTINUED

Member, Quality Assurance and Quality Control Committee J. G. Brown Cancer Center, University of Louisville	2006-2010
Chairman, Hematology and Medical Oncology Fellowship Committee J. G. Brown Cancer Center, University of Louisville	2004-2010
Chair, Genitourinary Oncology Group–CSRC J. G. Brown Cancer Center, University of Louisville	2001-2010
Member, Clinical Scientific Review Committee J. G. Brown Cancer Center, University of Louisville	2001-2010
Chairman, Hematology and Medical Oncology Fellow Selection Committee J. G. Brown Cancer Center, University of Louisville	2001-2010
Member, Pain Committee University of Louisville Hospital, Louisville, KY	2001-2010
Member, Taylor Regional Hospital Cancer Committee Taylor Regional Hospital, Campbellsville, KY	2003-2010
Member, Transfusion Medicine Faculty Search Committee University of Louisville, Louisville, KY	2004-2005
Member, International Medical Committee Jefferson County Medical Society, Kentucky	2001-2004
Advisor, Standards of Care Committee, Kentucky Cancer Program Kentucky Governor’s Breast Care Task Force	2001
Member, Medical Records Committee Meridia Huron Hospital, Cleveland, Ohio	1994-1997

CONTINUED

AWARDS AND NAMED LECTURESHIPS

HONORS AND AWARDS:

Potential for Major Clinical Applications, Second Place “A Phase I Study of AS1411 (AGRO100) in Advanced Cancer” Research!Louisville 2005, Louisville, KY	2005
Fellow of the American College of Physicians ACP, Philadelphia, PA	2005
Best Teaching Faculty Award Division of Medical Oncology and Hematology J. G. Brown Cancer Center, University of Louisville	2003
Certificate of Merit, Associates Abstract Competition American College of Physicians, Columbus, OH	1996
Honorable Mention Award, Meridia Huron Hospital Resident Essay Competition Meridia Huron Hospital, Cleveland, Ohio	1996

SELECTED LECTURES:

“Follicular Lymphoma” Hematology/Oncology Conference San Juan City Hospital, San Juan, PR	5/4/2017
“Atypical Hemolytic Uremic Syndrome” Medicine Grand Rounds Florida Hospital, Winter Park, FL	4/20/2016
“Multiple Myeloma” Hematology/Oncology Conference San Juan City Hospital, San Juan, PR	3/3/2016
“Update in Multiple Myeloma” Hematology/Oncology Grand Rounds Marshall University, Huntington, WV	2/19/2016

CONTINUED

“Colorectal Cancer” Hematology/Oncology Conference San Juan City Hospital, San Juan, PR	3/26/2015
“Understanding Testing and Monitoring in Chronic Myeloid Leukemia” Internal Medicine Conference, Case Western Reserve University Program St. Vincent Charity Hospital, Cleveland, OH	3/20/2015
“Renal-Cell Carcinoma, Translating the Science into Patient Care” Internal Medicine Grand Rounds The University of South Florida, Tampa, FL	8/14/2014
“Renal-Cell Carcinoma” Internal Medicine Grand Rounds Orlando Regional Medical Center, Orlando, FL	2/27/2014
“Heparin Induced Thrombocytopenia, Awareness Can Save Lives...” Internal Medicine Grand Rounds The University of South Florida, Tampa, FL	11/7/2013
“Hemorrhage, Related to Anticoagulants” Internal Medicine Grand Rounds The University of Oklahoma, Schusterman Campus, Tulsa, OK	1/20/2012
“Advances in Renal Cell Carcinoma” Medicine Grand Rounds Hillcrest Medical Center, Tulsa, OK	11/9/2011
“Renal Cell Carcinoma, Translating the Science into Patient Care” Surgery Grand Rounds The University of Oklahoma, St. John Medical Center, Tulsa, OK	9/7/2011
“Heparin Induced Thrombocytopenia” Internal Medicine Grand Rounds The University of Oklahoma, Schusterman Campus, Tulsa, OK	7/8/2011

CONTINUED

“Prostate Cancer” Internal Medicine Grand Rounds The University of Oklahoma, Schusterman Campus, Tulsa, OK	1/21/2011
“Hemorrhage, Related to Anticoagulants” Hematology Grand-Rounds University of Louisville, Kentucky	10/23/2009
“Renal-Cell Carcinoma, Translating the Science into Patient Care” Internal Medicine Grand-Rounds University of Louisville, Kentucky	9/24/2009
“Advances in Prostate Cancer” Medicine Grand Rounds The Methodist Hospital, Houston, TX	6/10/2009
“Advances in Prostate Cancer” Internal Medicine Grand Rounds Huron Hospital, Cleveland, OH	5/18/2008
“Update in Castrate-Resistant Prostate Cancer” Internal Medicine Grand Rounds Trinity Hospital, Minot, ND	5/8/2008
“Anticoagulation: Current Standards & Future Trends” 2007 Hemostasis and Thrombosis Symposium Galt House East, Louisville, KY	10/20/2007
“Genitourinary and Gastrointestinal Malignancies” 2007 Annual Louisville Update in Oncology, ASCO Review Galt House East, Louisville, KY	9/08/2007
“From Bench to Bedside in Louisville: AS1411, a Novel Cancer Therapy that Targets Nucleolin” Biomarkers, Genetics and Chemoprevention Seminar J G Brown Cancer Center Memorial Lecture Series, Louisville, KY	1/16/2007

CONTINUED

“Current Controversies in Diagnosis and Management of Prostate Cancer” Internal Medicine Update 2006, Norton Healthcare and University of Louisville The Marriott Hotel, Louisville, KY	12/01/2006
“Genitourinary and Gastrointestinal Malignancies” Second Annual Louisville Update in Oncology, ASCO Review The Marriott Hotel, Louisville, KY	6/11/2006
“Advances in the Treatment of Prostate Cancer” Seventh Annual Anatomic Pathology Update The Galt House East Hotel, Louisville, KY	5/20/2006
“An Update on Advances with Multikinase Inhibitors in Renal Cell Cancer” Hematology-Oncology Grand Rounds University of Cincinnati, Ohio	4/07/2006
“Advances in Systemic Therapy for Colorectal Cancer” Colorectal Surgery Conference University of Louisville, Kentucky	2/20/2006
“Update in General Hematology” First Annual Louisville Update in Hematology, ASH Review The Camberley Brown Hotel, Louisville, KY	2/04/2006
“Management of Renal Cell Carcinoma” Long Island International Oncology Network Meeting Long Island, New York	2/01/2006
“Molecular Targeted Therapies for Renal Cell Carcinoma” Tumor Board Baptist Montclair Medical Center, Birmingham, AL	1/30/2006
“Advances in Prostate Cancer” Man to Man-Louisville Prostate Cancer Support Group Baptist Hospital East Cancer Center, Louisville, KY	9/10/2005
“Research Advances in Genitourinary and Gastrointestinal Malignancies” First Annual Louisville Update in Oncology, ASCO Review The Camberley Brown Hotel, Louisville, KY	6/11/2005

CONTINUED

“Advances in Systemic Therapy for Colorectal Cancer” Colorectal Surgery Conference University of Louisville, Kentucky	4/18/2005
“Innovations and Clinical Trials in Colorectal Cancer” Symposium: Progress in the Treatment of Colorectal Cancer Norton Hospital, Louisville, KY	3/19/2005
“Heparin Induced Thrombocytopenia in Louisville” First Annual Louisville Update in Hematology The Camberley Brown Hotel, Louisville, KY	2/26/2005
“Advances in Prostate Cancer” BIOC-675/875 Cancer Biology Course, Graduate Program Department of Molecular Biology, University of Louisville	2/11/2005
“Advances in Prostate Cancer” Internal Medicine Grand-Rounds University of Louisville, Kentucky	5/06/2004
“Advances in Treatment Strategies for Prostate Cancer” Campbesville, Kentucky	3/09/2004
“New Strategies for Prostate Cancer Treatment: A Multi-Modality Approach” Louisville, Kentucky	2/05/2004
“Update in Heparin Induced Thrombocytopenia” Cardiology Grand-Rounds University of Louisville, Kentucky	1/29/2004
“VEGF: An Emerging Target for Anticancer Therapy” Medical Oncology Multi-Modality Conference J. G. Brown Cancer Center, University of Louisville, Kentucky	1/29/2004
“Update in the Management and Diagnosis of Deep Vein Thrombosis” Internal Medicine Update 2002, Norton Healthcare and University of Louisville Louisville, Kentucky	11/15/2002

CONTINUED

“Maximizing Oncologic Therapy. A focus on Prostate Cancer” Tennessee Pharmacist Association Meeting Nashville, Tennessee	8/22/2002
“Prostate Cancer” Oncology Symposium on Breast, Prostate and Lung Cancer University of Louisville, Kentucky	6/1/2002
“Advances in Prostate Cancer” Internal Medicine Grand-Rounds University of Louisville, Kentucky	10/24/2001
“Platinum Compounds” University of Louisville, James Graham Brown Cancer Center Louisville, Kentucky	7/14/2000
“Thrombotic Thrombocytopenic Purpura, from Moschcowitz to Clopidogrel” Hematology Conference, University of Louisville, James Graham Brown Cancer Center Louisville, Kentucky	7/14/2000
“Thrombotic Thrombocytopenic Purpura, from Moschcowitz to Clopidogrel” Hematology/Oncology Research Conference, University of Alabama at Birmingham Birmingham, Alabama	6/15/2000
“Aspergillus in AML” Intra-City Hematology Conference Houston, Texas	4/5/2000
“Anti-RhD IVIG for the treatment of ITP” Intra-City Hematology Conference Houston, Texas	3/15/2000
“Anaplastic Large Cell Lymphoma” Intra-City Hematology Conference Houston, Texas	12/15/1999
“Therapeutic Plasma Exchange” Intra-City Hematology Conference Houston, Texas	10/6/1999

CONTINUED

“Hemochromatosis” Intra-City Hematology Conference Houston, Texas	6/30/1999
“Autoimmune Hemolytic Anemias” Hematology Intra-City Conference Houston, Texas	5/12/1999
“Waldenstrom’s Macroglobulinemia” Intra-City Hematology Conference Houston, Texas	4/14/1999
“Molecular Oncology” Baylor College of Medicine Didactic Conference Houston, Texas	11/12/1998
“Thyroid Cancer” Baylor College of Medicine Didactic Conference Houston, Texas	5/7/1998
“Solid Tumors of Childhood” Baylor College of Medicine Didactic Conference Houston, Texas	3/12/1998
“Tumor Markers” Baylor College of Medicine Didactic Conference Houston, Texas	11/6/1997
“Staging of Lung Cancer” Veterans Affairs Medical Center Oncology Conference Houston, Texas	8/13/1997

MILITARY SERVICE:

None

CONTINUED

BIBLIOGRAPHY:

ARTICLES PUBLISHED IN PEER-REVIEWED JOURNALS:

1. Laber DA, Ravakhah K, Smith HR. Acne conglobata causing ankylosis of the wrists and ankylosing spondylitis. *Journal of Clinical Rheumatology* 1999;5:169-71
2. Laber DA. Radiotherapy for Small-Cell Lung Cancer. *New England Journal of Medicine* 1999;340(25):2003-4
3. Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC Jr, Tezcan H, Waples J, Ward J, Yee LK. A Randomized Controlled Trial of Darbepoetin Alfa Administered as a Fixed or Weight-Based Dose Using a Front-Loading Schedule in Patients with Anemia Who Have Nonmyeloid Malignancies. *Cancer* 2004;100(4):859-68
4. Makoni SN, Laber DA. Clinical Spectrum of Myelophthisis in Cancer Patients. *American Journal of Hematology* 2004;76(1)92-93
5. Laber DA, Martin ME. Etiology of Thrombocytopenia in All Patients Treated with Heparin Products. *European Journal of Haematology* 2005;75:101-105
6. Laber DA, Kloecker GH, Bhupalam L. Advances in the Management of Metastatic Androgen Independent Prostate Cancer. *Journal of the Kentucky Medical Association* 2006;104:65-69
7. Martin ME, Laber DA. Cefotetan-induced Hemolytic Anemia after Perioperative Prophylaxis. *American Journal of Hematology* 2006;81(3):186-188
8. Laber DA. Why Did He Die? *Cancer Investigation* 2006;24(3):331-332
9. Fentress DS, Orrico LA, Kruspe M, Briscoe K, Laber DA. Multiple Myeloma. *Hospital Physician* 2006;42(5):15-25
10. Morgan JS, Laber DA. Salmonella Bacteremia in an Adult with Sickle Cell Disease. *Southern Medical Journal* 2006;99(6):635-627

CONTINUED

11. Laber DA, Glisson SD, Hargis JB, Kosfeld RE, Goldsmith G, Cervera A, La Rocca RV. Higher Dose Docetaxel in Androgen Independent Prostate Cancer. *American Journal of Clinical Oncology* 2006;29(4):389-394
12. Laber DA, Okeke RI, Arce-Lara C, Taft BS, Schonard CL, McMasters KM, Kloecker GH, Miller DM. Thalidomide and Temozolomide in the Treatment of Advanced Melanoma. *Journal of Cancer Research and Clinical Oncology* 2006;132(9):611-6
13. Laber DA. Risk Factors, Classification and Staging of Renal Cell Cancer. *Medical Oncology* 2006;24(4):443-454
14. Martin ME, Kloecker GH, Laber DA. Argatroban for Anticoagulation during Cardiopulmonary Bypass. *European Journal of Haematology* 2007;78(2):161-165
15. Choudry MA, Moffett B, Laber DA. Pure Red Cell Aplasia Secondary to Pregnancy and Medroxyprogesterone: Characterization of a Syndrome. *Annals of Hematology* 2007;86:233-237
16. Rabinowits G, Shuster TD, Pazianos AG, Laber DA. The Extremely Indolent Course of a Thymic Carcinoid. *Journal of Clinical Oncology* 2007;25:1138-1139
17. Kloecker GH, Studts JL, Laber DA, Bousamra M. Lung Cancer in the US and in Kentucky. *Journal of the Kentucky Medical Association* 2007;105(4):107-112
18. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *New England Journal of Medicine* 2007;356(22):2271-81. Appendix: In addition to the authors, Laber DA was an investigator and enrolled patients in the Global Advanced Renal-Cell Carcinoma Trial
19. Laber DA, Khan MI, Kloecker GH, Schonard C, Taft BS, Salvador C. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. *Cancer Biology & Therapy* 2007;6(6):840-5
20. Wagner SA, Mehta AC, Laber DA. Rituximab Induced Interstitial Lung Disease. *American Journal of Hematology* 2007;82(10):916-9

CONTINUED

21. Laber DA. Rapid Response: Vitamin E and Prostate Cancer. Supplemental and Dietary Vitamin E Intakes and Risk of Prostate Cancer in a Large Prospective Study: Wright ME, Weinstein SJ, Lawson KA, et al. Cancer Epidemiol Biomarkers Prev 2007;16:1128-1135. South Med J. 2008 Jan;101(1):4-5
22. Slone S, Martin AW, Wellhausen SR, Woods DR, Malone JC, Lear SC, Laber DA. IL-4 Production by CD8+ Lymphomatoid Papulosis, Type C, Attracts Background Eosinophils. Journal of Cutaneous Pathology 2008. Oct;35 Suppl 1:38-45
23. Cramer DE, Wagner S, Li B, Liu J, Hansen R, Reza R, Wu W, Zuba Surma E, Laber D, Ratajczak MZ, Yan J. Mobilization of Hematopoietic Progenitor Cells by Yeast-derived beta-Glucan Requires Activation of Matrix Metalloproteinase-9. Stem Cells. 2008 May;26(5):1231-40
24. Laber DA. Bhupalam L, Kloecker GH. Transient and Spontaneous Factor V Inhibitor. The Open Hematology Journal 2008;2:86
25. Harandi A, Laber DA. Historical Perspective and Advances in the Treatment of Multiple Myeloma. Oncology Reviews 2008;2:253-261
26. Rezazadeh A, Kloecker GH, Kannan CR, Laber DA. Brain Stem and Clivus Plasmacytoma. The American Journal of the Medical Sciences 2008;336(6):503
27. Laber DA, Mushtaq M. Compassionate Use of Sorafenib in Patients with Advanced Renal Cell Cancer. Clinical Genitourinary Cancer 2009;7(1):34-38
28. Rabinowits G, Laber DA. Bladder Cancer: Clinical Practice. Journal of the Kentucky Medical Association 2009;107(4):129-33
29. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology 2009;2009:567486. Epub 2009 May 6
30. Khan MI, Chesney JA, Laber DA, Miller DM. Digitalis, a targeted therapy for cancer? The American Journal of the Medical Sciences 2009;337(5):355-9
31. Jaglal MV, Laber DA, Arnold FW, Miller DM, Chesney JA, Kloecker GH. Obtaining Routine Blood Cultures During Interleukin-2-Containing Therapy Is Unnecessary. American Journal of Clinical Oncology 2009;32(4):429-31

CONTINUED

32. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. *Experimental Molecular Pathology* 2009;86(3):151-64
33. Rezazadeh A, Laber DA, Jenson AB, Ghim S, Kloecker GH. The Role of Papilloma Virus in Lung Cancer: A Review of the Evidence. *The American Journal of the Medical Sciences* 2009;338(1):64-7
34. Moffett PU, Moffett BK, Laber DA. Diagnosing and managing suspected malignant pleural effusions. *The Journal of Supportive Oncology*. 2009;7(4):143-6
35. Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA. Fixed-Dose Every-Other-Week Capecitabine and Oxaliplatin for Refractory Squamous Cell Carcinoma of the Head and Neck. *The American Journal of the Medical Sciences* 2010;339(2):148-51
36. Storey RE, Huerta AL, Khan A, Laber DA. Spontaneous complete regression of hepatocellular carcinoma. *Med Oncol*. 2011 Dec;28(4):948-50
37. Kayali F, Janjua MA, Laber DA, Miller DM, Kloecker GH. Phase II trial of second line erlotinib and digoxin for nonsmall cell lung cancer. *Open Access Journal of Clinical Trials*. 2011;3:9-13
38. Zhang W, Rabinowits G, Laber DA, Kloecker GH. Effect of zoledronic acid on tartrate-resistant acid phosphatase isoform type 5b and other bone markers in lung cancer patients with bone metastases. *Pathology and Laboratory Medicine International*. 2012;4:5-11
39. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN Jr, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. *Investigational New Drugs*. 2014 Feb;32(1):178-87a
40. Molander L, Caraway C, Linderbeck L, Laber DA. Cerebrospinal Fluid (CSF) Directed Antineoplastic Agents: A Review of Current Knowledge. *J Cancer Prev Curr Res* 2015 2(2): 00026. DOI: 10.15406/jcpcr.2015.02.00026
41. Visweshwar N, Jaglal M, Booth C, Griffin P, Laber D. Paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia.. *Ann Hematol*. 2016 Oct;95(10):1747-9

CONTINUED

42. Visweshwar N, Malachowski S, Jaglal M, Laber D. Is warfarin obsolete? SM J Oncol Hematol.. 2016; 1(1): 1002
43. Visweshwar N, Malachowski S, Patel A, Jaglal M, Laber D. Accidental and surreptitious intake of oral anticoagulants including older and newer agents –A diagnostic dilemma. J Hematol Thromb 2017;3(1):3
44. Sam C, Desai P, Laber D, Patel A, Visweshwar N, Jaglal M. Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Transfus Med. 2017 Apr 12. doi: 10.1111/tme.12407

ARTICLES IN A BOOK, PAMPHLET OR BULLETIN:

1. Laber DA, Miller DM. Editorial: Tratamiento adjuvante del melanoma maligno. In: Muse IM, Viola Alles A, Sabini G (eds.); Aspectos Practicos de la Clinica Oncologica. Montevideo, Uruguay, Editorial Sudamericana, April 2004, pp. 396-298.
2. Fentress DS, Orrico LA, Kruspe M, Briscoe K, Laber DA. Clinical Review Quiz: Multiple Myeloma. Hospital Physician 2006;42(5):26, 36.
3. Laber DA. Heparin-Induced Thrombocytopenia in Louisville. Louisville Medicine 2006;54(8):363-364
4. Laber DA. Self-Assessment in Oncology. Renal-Cell Carcinoma: Review Questions. Hospital Physician 2007;43(4):37-39
5. Rabinowits G, Laber DA. Self-Assessment in Oncology. Bladder Cancer: Review Questions. Hospital Physician 2008;44(3):39-41
6. Makoni SN, Laber DA. Bone Marrow Failure. In: Walsh TD, Caraceni AT, Fainsinger R, Foley KM, Glare P, Goh C, Lloyd-Williams M, Nunez Olarte J, Radbruch L (eds.); Palliative Medicine. Elsevier Science, Unites States, August 2008, chapter 229.

PUBLISHED ABSTRACTS:

1. Laber DA, Rice L. Anti-D immune globulin can precipitate severe hemolysis in immune thrombocytopenia purpura (ITP) patients with occult Evans' syndrome. *Blood* 1999;94:10(supplement1):3521a
2. Carwile JM, Laber DA, Soltero ER, Anstadt MP, Chow TW, Nolasco LH, Kroll MH, Moake JL. Thrombotic thrombocytopenic purpura occurring after exposure to clopidogrel. *Blood* 1999;94:10(supplement1):3506a
3. Laber DA, La Rocca RV, Glisson S, Hargis J, Schonard C. Phase II study of higher dose docetaxel in clinically deteriorating patients with hormone refractory prostate cancer. *Proceedings of the American Society of Clinical Oncology* 2002:2449a
4. Choudry MA, Kantelhardt SR, Laber DA, Sharma VR. Eosinophilia Associated with Chronic Pancreatitis Exacerbation. *Blood* 2002;100:11(supplement1):3636a
5. Kloecker GH, Laber DA, Bhupalam L. A Case of Transient and Spontaneous Factor V Inhibitor. *Blood* 2002;100:11(supplement1):3892a
6. Feng Y, Laber DA, Hendler FJ. Severe Thrombosis in a Young Man with a Homozygous Prothrombin G20210A Mutation. *Blood* 2002;100:11(supplement1):3929a
7. Salvador C, Laber DA. Unreliability of Weight-Based Dosing of Low-Molecular-Weight-Heparin During Pregnancy. *Blood* 2002;100:11(supplement1):3962a
8. Khan D, Laber DA, Yam L. Use of High Dose Warfarin in a Patient with Warfarin Resistance. *Blood* 2002;100:11(supplement1):4010a
9. Martin ME, Laber DA, Stapp DE, Lockwood WB. Drug Induced Hemolytic Anemia with Antibiotic Prophylaxis. *Blood* 2002;100:11(supplement1):4020a
10. Khan D, Sharma VR, Laber DA. The Clinical Spectrum of Granulocytic Sarcoma. *Blood* 2002;100:11(supplement1):4550a
11. Devabhaktuni YD, Laber DA. Secondary Plasma Cell Leukemia Associated with Thalidomide in a Patient with Multiple Myeloma. *Blood* 2002;100:11(supplement1):5100a

CONTINUED

12. Laber DA, La Rocca RV, Glisson SD, Hargis J, Schonard C. Higher dose docetaxel in patients with hormone refractory prostate cancer (HRPC). Long-term results of a phase II study. Proceedings of the American Society of Clinical Oncology 2003:1661a
13. Mehta AC, Laber DA, McMasters KM, Taft B, Coons D, Miller DM. A phase II study of temozolomide and thalidomide in the treatment of advanced melanoma. Proceedings of the American Society of Clinical Oncology 2003:2907a
14. Laber DA, Martin ME. How Aware Are Physicians of Heparin-Induced Thrombocytopenia? Blood 2003;102:11(supplement):4021a
15. Martin ME, Laber DA. Incidence of Heparin Induced Thrombocytopenia in All Patients Receiving Heparin and Low-Molecular Weight Heparin. Blood 2003;102:11(supplement):4022a
16. Makoni SN, Laber DA. Clinical Spectrum of Myelophthisis in Cancer Patients. Blood 2003;102:11(supplement):4423a
17. Moffett PU, Jaggernauth S, Laber DA. A Case of Idiopathic Myelofibrosis and Ulcerative Colitis in a Young Man: What Role Do Cytokines Play? Blood 2003;102:11(supplement):5072a
18. Laber DA, Choudry MA, Taft BS, Bhupalam L, Sharma VR, Hendler FJ, Barnhart KM. A Phase I Study of AGRO100 in Advanced Cancer. Proceedings of the American Society of Clinical Oncology 2004:3112a
19. Barnhart KM, Laber DA, Bates PJ, Trent JO, Miller DM. AGRO100: the Translation from Lab to Clinic of a Tumor-Targeted Nucleic Acid Aptamer. Proceedings of the American Society of Clinical Oncology 2004:3126a
20. Choudry MA, Chilakapati V, Crump C, Bunner R, Hendler FJ, La Rocca RV, Bhupalam L, Sharma VR, Miller DM, Laber DA. Phase II Study of Cyclophosphamide, Etoposide and Estramustine (CEE) in Patients with Androgen Independent Prostate Cancer (AIPC). Proceedings of the American Society of Clinical Oncology 2004:4708a
21. Salvador C, Bhupalam L, Taft B, Frantz J, Schonard C, Sharma VR, Hendler FJ, Miller DM, Laber DA. A Phase I Study of Thalidomide, Capecitabine and Temozolomide (TCT) in Advanced Cancer. Proceedings of the American Society of Clinical Oncology 2004:3141a

CONTINUED

22. Bhupalam L, Jagernauth S, Laber DA. Successful Treatment of a Patient with Unresectable Olfactory Neuroblastoma: A Case Report and Literature Review. Proceedings of the American Society of Clinical Oncology 2004:5620a
23. Hayek FN, Bhupalam L, Paris KJ, Goldsmith LJ, Hendler F, Laber DA, Jose BO, Silverman C, Bumpous JM, Khan Z, Miller DM, Spanos W. Phase II Trial of Weekly Paclitaxel and Carboplatin Chemotherapy along with Radiation and Amifostine in Patients with Locally Advanced Head and Neck Cancer. Lung Cancer 2004;46(supplement 1):S71
24. Hayek F, Bhupalam L, Jose BO, Bumpous J, Hendler F, Laber DA, Silverman C, Goldsmith L, Miller DM, Spanos W. Phase II Trial Of Weekly Paclitaxel And Carboplatin Chemotherapy Along With Radiation And Amifostine In Patients With Locally Advanced Head And Neck Cancer. Research!Louisville 2004. November 8-12, 2004: RES2. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
25. Choudry MA, Crump C, Mehta A, Hendler F, Sharma V, Miller DM, Laber DA . Phase II Study of Cyclophosphamide, Etoposide and Estramustine (CEE) in Patients with Androgen Independent Prostate Cancer (AIPC). Research!Louisville 2004. November 8-12, 2004: PRF5. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
26. Laber ER and Laber DA. Detailed Analysis of Neutropenic Risk Factors in Patients with Prostate Cancer Treated with Chemotherapy. Blood 2004 (supplement):3804a
27. Choudry MA, Laber DA, Kloecker GH, Mehta AC, Crump C, Bhupalam L, La Rocca RV, Sharma VR, Hendler FJ, Miller DM. Phase II Study of Cyclophosphamide, Etoposide and Estramustine in Patients with Androgen Independent Prostate Cancer. Proceedings of the 2005 Prostate Cancer Symposium 2005:298a
28. Laber DA, Glisson SD, Hargis JB, Kosfeld RE, Goldsmith G, Cervera A, La Rocca RV. Phase II study of higher dose docetaxel in androgen independent prostate cancer. Proceedings of the 2005 Prostate Cancer Symposium 2005:300a
29. Laber DA, Sharma VR, Bhupalam L, Taft B, Hendler FJ, Barnhart KM. Update on the First Phase I Study of AGRO100 in Advanced Cancer. Journal of Clinical Oncology 2005;23:16(supplement):3064a

30. Choudry MA, Laber DA, Kloecker GH, Mehta AC, Crump C, Bhupalam L, La Rocca RV, Sharma VR, Hendler FJ, Miller DM. Phase II Study of Cyclophosphamide, Etoposide and Estramustine in Patients with Androgen Independent Prostate Cancer. *Journal of Clinical Oncology* 2005;23:16(supplement):4757a
31. Glisson SD, Laber DA, Hargis JB, Kosfeld RE, Goldsmith G, Cervera A, La Rocca RV Final results of a phase II study of higher dose docetaxel in androgen independent prostate cancer. *Journal of Clinical Oncology* 2005;23:16(supplement):4759a
32. Okeke IR, Laber DA, Taft B, McMasters KM, Miller DM. Temozolomide and thalidomide in the treatment of advanced melanoma, a phase II study. *Journal of Clinical Oncology* 2005;23:16(supplement):7573a
33. Bhupalam L, Laber DA, Hokensmith D, Paris K, Flynn M, Goldsmith J, Khan Z, Hendler F, Jose BO, Spanos W. Concurrent Paclitaxel Carboplatin and Radiotherapy Followed by Chemotherapy or Surgery in Patients with Locally Advanced Head and Neck Cancer. *Research!Louisville* 2005. October 31- November 4, 2005: F5.
<http://ocrss.louisville.edu/clients/hscro/conspectus/search>
34. Laber DA, Taft B, Barnhart K, Kloecker GH, Miller DM. A Phase I Study of AS1411 (AGRO100) in Advanced Cancer. *Research!Louisville* 2005. October 31- November 4, 2005: F31. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
35. Khan MI, Salvador C, Laber DA. A Phase I Study of Thalidomide, Capecitabine and Temozolomide (TCT) in Advanced Cancer. *Research!Louisville* 2005. October 31- November 4, 2005: CRF4. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
36. Martin ME, Laber DA. A Phase I/II Study of Docetaxel in Combination with Doxorubicin HCl Liposome Injection (Doxil) in Advanced Androgen-Independent Prostate Cancer. *Research!Louisville* 2005. October 31- November 4, 2005: CRF7.
<http://ocrss.louisville.edu/clients/hscro/conspectus/search>
37. Mushtaq M, Ferguson L, Taft B, Williams D, Laber DA. Sorafenib in Patients with Advanced Renal Cell Cancer. The Expanded Access Program Experience at the Brown Cancer Center. *Research!Louisville* 2005. October 31- November 4, 2005: CRF8.
<http://ocrss.louisville.edu/clients/hscro/conspectus/search>

38. Wagner S, Mehta A, Laber DA. Rituximab-Induced Interstitial Lung Disease. Research!Louisville 2005. October 31- November 4, 2005: CRF11.
<http://ocrss.louisville.edu/clients/hscro/conspectus/search>
39. Zhong W, Laber DA, Silverman C, Taft B, Lilly B, Bhupalam L. Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies. Research!Louisville 2005. October 31- November 4, 2005: CRF12.
<http://ocrss.louisville.edu/clients/hscro/conspectus/search>
40. Laber DA, Bates PJ, Trent JO, Barnhart K, Taft B, Miller DM. Long Term Clinical Responses in Renal Cell Carcinoma Patients Treated with Quadriplex Forming Oligonucleotides. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Philadelphia, PA. November 14-18, 2005; B228
41. Hayek FN, Wagner SA, Laber DA, Sharma VR. Interferon- α -Associated Acquired Factor VIII Inhibitor. Blood 2005;106:11(supplement):4093a
42. Martin ME, Kloecker GH, Patel A, Laber DA. Argatroban for Anticoagulation during Cardiopulmonary Bypass. Blood 2005;106:11(supplement):4150a
43. Wagner SA, Makani SS, Laber DA. Rituximab Induced Interstitial Lung Disease. Blood 2005;106:11(supplement):4768a
44. Rezazadeh A, Kloecker GH, Laber DA. Multiple Myeloma Presenting as a Clivus and Brain Stem Plasmacytoma. Blood 2005;106:11(supplement): 5061a
45. Martin ME, Laber DA. A phase I Study of Docetaxel in Combination with Doxorubicin HCl Liposome Injection in Advanced Androgen Independent Prostate Cancer. Proceedings of the 2006 Prostate Cancer Symposium 2006:234a
46. Moffett PU, Choudry MA, Ferguson LA, Williams DA, La Rocca RV, Hendler FJ, Laber DA. Update on a Phase II Study of Cyclophosphamide, Etoposide and Estramustine in Patients with Androgen Independent Prostate Cancer. Journal of Clinical Oncology 2006;24:18(supplement):4647a
47. Laber DA, Taft BS, Kloecker GH, Bates PJ, Trent JO, Miller DM. Extended Phase I Study of AS1411 in Renal and Non-Small Cell Lung Cancers. Journal of Clinical Oncology 2006;24:18(supplement):13098a

CONTINUED

48. Khan MI, Salvador C, Schonard CL, Taft BS, Kloecker GH, Laber DA. A Phase I Study of Thalidomide, Capecitabine and Temozolomide (TCT) in Advanced Cancer. Journal of Clinical Oncology 2006;24:18(supplement):13122a
49. Martin ME, Ferguson LA, Williams DA, Laber DA. A Phase I/II Study of Docetaxel in Combination with Doxorubicin HCL Liposome Injection in Advanced Androgen-Independent Prostate Cancer. Journal of Clinical Oncology 2006;24:18(supplement):14588a
50. Laber DA, Martin ME, Kloecker GH. Proposed Guidelines for Anticoagulation during Cardiac Surgery Using Argatroban. Haematologica 2006;92(supplement):413a
51. Laber DA, Moffett BK, Choudry MA. Pregnancy-Induced Pure Red-Cell Aplasia, A Distinct Syndrome. Haematologica 2006;92(supplement):553a
52. Khan MI, Salvador C, Taft B, Schonard C, Kloecker GH, Laber DA. A Phase I Study of Thalidomide, Capecitabine and Temozolomide (TCT) in Advanced Cancer. Research!Louisville 2006. October 10-13, 2006: CRF9. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
53. Moffett P, Choudry M, Ferguson L, Williams D, LaRocca R, Hendler F, Laber DA. Update on a Phase II Study of Cyclophosphamide, Etoposide and Estramustine in Patients with Androgen Independent Prostate Cancer. Research!Louisville 2006. October 10-13, 2006: CRF12. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
54. Mushtaq M, Ferguson L, Laber DA. Sorafenib in Patients with Heavily Pretreated Advanced Renal Cell Carcinoma. Research!Louisville 2006. October 10-13, 2006: CRF13. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
55. Wagner S, Cramer D, Hansen R, Reca R, Ratajczak M, Li B, Laber DA, Yan J. Beta Glucan Enhances Hematopoietic Stem Cell Mobilization. Research!Louisville 2006. October 10-13, 2006: CRF17. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
56. Zhong W, Laber DA, Bumpous J, Lentsch E, Silverman C, Lilly B, Sheffield J, Goldsmith L, Hendler F, Bhupalam L. Phase II Study Of Bi-Weekly Capecitabine And Oxaliplatin In Recurrent Head And Neck Squamous Cell Cancer. Research!Louisville 2006. October 10-13, 2006: CRF18. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>

CONTINUED

57. Wagner S, Cramer D, Hansen R, Reca R, Ratajczak M, Li B, Laber DA, Yan J. Beta Glucan Enhances Hematopoietic Stem Cell Mobilization. *Blood* 2006;108:11(supplement): 1348a
58. Rezazadeh A, Hollensead SC, Laber DA, Kloecker GH. Intracranial Hememorrhage in a Patient with Osteogenesis Imperfecta Due to Inherited and Acquired Platelet Dysfunction. *Blood* 2006;108:11(supplement): 3960a
59. Laber DA, Ferguson L, Martin ME. A phase II study of docetaxel in combination with doxorubicin HCl liposome injection in advanced androgen-independent prostate cancer. *Proceedings of the 2006 Prostate Cancer Symposium* 2007:241a
60. Khan MI, Taft B, Rasku MA, Laber DA, Chesney J, Miller DM. A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon, and digoxin in melanoma patients. *Journal of Clinical Oncology* 2007;25:18(supplement):8573.a
61. Rezazadeh A, Laber DA, Sharma VR, Kloecker GH. Amyloidosis Presenting with Platelet Dysfunction and Recurrent Retroperitoneal Hemorrhage (RH). *Blood* 2007;110:11(supplement): 3944a
62. Laber DA, Perisetti NM, Ferguson LA, Kloecker GH. A Phase II Study of Docetaxel in Combination with Doxorubicin HCl Liposome Injection (Doxil) in Metastatic Androgen-Independent Prostate Cancer. *Proceedings of the 2008 Prostate Cancer Symposium* 2008:159a
63. Rezazadeh A, Desai PC, Laber DA, Ghim S, Schaefer G, Jenson AB, Kloecker GH. Detection of HPV in different subtypes of non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology* 2008;26:15(supplement): 22098.a
64. Khan MI, Laber DA, Chesney J, Taft B, Miller DM. A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon, and digoxin in melanoma patients. *Journal of Clinical Oncology* 2008;26:15(supplement): 20021.a
65. Jarboe J, Laber DA. A Systematic Review of Disseminated Intravascular Coagulopathy Assoicated with Prostate Cancer. *Research!Louisville* 2008. October 20-24, 2008: RES-7. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>
66. Abdolmohammadi A, Laber DA. The University of Louisville Bladder Cancer Study. *Research!Louisville* 2008. October 20-24, 2008: RES-16. <http://ocrss.louisville.edu/clients/hscro/conspectus/search>

CONTINUED

67. Rezazadeh A, Laber DA, Chesney JA, Miller DM. Digoxin plus biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa in patients with metastatic melanoma, a phase II study. Proceedings of the 7th World Congress on Melanoma. May 12-16 2009. Vienna, Austria.
68. Kayali F, Janjua MA, Laber DA, Miller DM, Day JM, Kloecker GH. Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2008;27(supplement): e19077)
69. Xiang D, Garbett NC, Chaires J, Laber DA, Kloecker GH. Plasma thermogram profiling: A novel biomarker for lung cancer. Journal of Clinical Oncology 2008;27(supplement): e22074
70. Michael F Driscoll, Derek Forster, Brandi Dyer, and Damian A. Laber. Iron Deficiency Anemia: Safety and Cost-Effectiveness of Treatment with Various Intravenous Iron Preparations. Blood 2008;112:4661
71. Kayali F, Janjua MA, Laber DA, Miller DM, Day JM, Kloecker GH. Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2009;27 (supplement): e19077
72. Xiang D, Garbett NC, Chaires J, Laber DA, Kloecker GH. Plasma thermogram profiling: A novel biomarker for lung cancer. Journal of Clinical Oncology 2009;27 (supplement): e22074
73. Rosenberg JE, Drabkin HA, Lara Jr. P, Harzstark AL, Figlin RA, Smith GW, Erlandsson F, Laber DA. A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology 2010;28 (supplement): 4590
74. Zhang W, Rabinowits G, Janckila AJ, Yam L, Hendler FJ, Laber DA, Li C, Kloecker GH. Effect of zoledronic acid on tartrate-resistant acid phosphatase isoform 5b (TRAP-5b) and other bone markers in lung cancer patients with bone metastasis. Journal of Clinical Oncology 2010;28 (supplement): e18118
75. Janjua MA, Kayali F, Jain D, Salvador C, Rabinowits G, Laber DA, Kloecker GH. A phase II trial of extended interval port-a-cath (PAC) flushes. Journal of Clinical Oncology 2010;28 (supplement): e19635

CONTINUED

76. Abdolmohammadi A, Maurisse R, Bedayat B, DeSemir D, Laber DA, Gruenert DC. Sequence-Specific Conversion of β^A - to β^S -Globin by Small Fragment Homologous Replacement In Hematopoietic Stem/Progenitor Cells. Blood 2010;116:3754
77. Zhang W, Shams M, Moffett P, Rabinowits G, Salvador C, Kloecker GH, Laber DA. Final results of a phase II study of cyclophosphamide, etoposide, and estramustine in patients with castration-resistant prostate cancer. Journal of Clinical Oncology 2011;29 (supplement): e15084

PRESENTATIONS:

1. Laber DA. Acne conglobata causing ankylosis of the wrists and ankylosing spondylitis. Oral presentation. American College of Physicians, Ohio Chapter. Columbus, Ohio. October 1996.
2. Laber DA. Higher dose docetaxel in patients with hormone refractory prostate cancer (HRPC). Long-term results of a phase II study. Poster session. 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. May 31-June 3, 2003.
3. Choudry MA, Laber DA (Mentor). Phase II Study of Cyclophosphamide, Etoposide and Estramustine in Patients with Androgen Independent Prostate Cancer. Poster session. Research!Louisville 2004. November 8-12, 2004. Honorable Mention Award.
4. Choudry MA, Laber DA. Phase II Study of Cyclophosphamide, Etoposide and Estramustine in Patients with Androgen Independent Prostate Cancer. Poster session. 2005 Prostate Cancer Symposium, Orlando, FL. February 17-19, 2005.
5. Laber DA. Phase II study of higher dose docetaxel in androgen independent prostate cancer. Poster session. 2005 Prostate Cancer Symposium, Orlando, FL. February 17-19, 2005.
6. Laber DA. Update on the First Phase I Study of AGRO100 in Advanced Cancer. Poster session. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL. May 13-17, 2005.
7. Laber DA. A Phase I Study of AS1411 (AGRO100) in Advanced Cancer. Faculty Research Day Poster Competition Winner, Second Place: Potential for Major Clinical Applications. Research!Louisville 2005. October 31- November 4, 2005.

CONTINUED

8. Martin ME, Laber DA. A phase I Study of Docetaxel in Combination with Doxorubicin HCl Liposome Injection in Advanced Androgen Independent Prostate Cancer. Poster session. 2006 Prostate Cancer Symposium, San Francisco, CA. February 24-26, 2006.
9. Moffett PU, Laber DA. Update on a Phase II Study of Cyclophosphamide, Etoposide and Estramustine in Patients with Androgen Independent Prostate Cancer. Poster session. 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA. June 2-6, 2006.
10. Laber DA. Proposed Guidelines for Anticoagulation during Cardiac Surgery Using Argatroban. Poster session. 11th Congress of the European Hematology Association. Amsterdam, The Netherlands. June 15-18, 2006.
11. Laber DA. Pregnancy-Induced Pure Red-Cell Aplasia, A Distinct Syndrome. Poster session. 11th Congress of the European Hematology Association. Amsterdam, The Netherlands. June 15-18, 2006.
12. Laber DA. A phase II study of docetaxel in combination with doxorubicin HCl liposome injection in advanced androgen-independent prostate cancer. Poster session. 2007 Prostate Cancer Symposium, Orlando, FL. February 22-24, 2007.
13. Laber DA, Perisetti NM, Ferguson LA, Kloecker GH. A Phase II Study of Docetaxel in Combination with Doxorubicin HCl Liposome Injection (Doxil) in Metastatic Androgen-Independent Prostate Cancer. Poster session. 2008 Prostate Cancer Symposium, San Francisco, CA. February 14-16, 2008.

RESEARCH FUNDING:

GRANT SUPPORT

HRSA H30MC24046-02-00, Southeast Region Comprehensive and Diagnostic Bleeding Disorders Treatment Center Program P.I.: Damian A. Laber	6/2013-5/2014 \$ 15,000
CDC 5U27DD000862-02, Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders P.I.: Damian A. Laber	9/2013-9/2014 \$ 10,000

CONTINUED

NIH K30HL004149, Clinical Research Curriculum Award (K30) 8/2000-7/2005
Clinical Research, Epidemiology & Statistical Training \$ 1,000,000
P.I.: Carlton A. Hornung
Role: Faculty

Kentucky Lung Cancer Research Program 9/2001-8/2004
"A Novel Marker and Therapeutic Target for Lung Cancer" \$ 150,000
P.I.: Paula J. Bates
Role: Co-Investigator

CLINICAL RESEARCH SUPPORT

1. USF IRB Study # Pro00005698: The Role of Myeloid Derived Suppressor Cells (MDSC) in Human Pancreatic Cancer Progression. 2015
Co Investigator.
Investigator initiated.
2. USF IRB#: Pro00016144: Pilot Study of Preoperative chemoradiation for glioblastoma. 2014-2015
Co Investigator.
Investigator initiated.
3. USF IRB#: Pro00015970: CDC Public Health Surveillance Project (CDC PHSP) for Bleeding Disorders: Population Profile, Mortality Reporting and the Registry for Bleeding Disorders Surveillance. 2013-2014
Principal Investigator at USF.
Sponsor: CDC. Budget \$ 10,000
4. HSPPO # 433-03 WIRB® Protocol #20031122: Phase 1 Study of AS1411 in Advanced Solid Tumors. 2005-2006
Principal Investigator.
Sponsor: Antisoma Research Ltd. Budget \$ 350,000
5. HSPPO # 433-03 APT-1-0603 WIRB® Protocol #20031122: Phase 1 Study of AGRO100 in Advanced Solid Tumors. 2003-2004
Principal Investigator.
Sponsor: Aptamera, Inc. Budget \$ 250,327

CONTINUED

6. HSPPO # 03.0252: A Study of Circulating Nerve Growth Factor in Patients with Prostate Cancer.
Principal Investigator. 2003-2008
Investigator initiated.
7. HSC # 398-02: Evaluation of a Novel Cancer Marker.
Principal Investigator. 2002-2004
Sponsor: Kentucky Lung Cancer Research Fund. Budget \$150,000
8. HSC # 415-02: A Study of Nucleolin Stained Sputum Samples in Patients with Lung Cancer or Pulmonary Metastasis, and in Patients at High Risk for Lung Cancer or Pulmonary Metastasis.
Principal Investigator. 2002-2004
Sponsor: Kentucky Lung Cancer Research Fund. Budget \$150,000
9. HSPPO # 312-01: A Retrospective Study of Heparin-Induced Thrombocytopenia (HIT) and Thrombosis Syndrome (TS).
Principal Investigator. 2001-2004
Investigator initiated.
10. HSPPO # 03.0575: Phase I/II Study of Docetaxel (Taxotere) in Combination with Doxorubicin HCl Liposome Injection (Doxil) in Advanced Androgen-Independent Prostate Cancer (AIPC).
Principal Investigator. 2003-2009
Sponsors: Ortho-Biotech and Sanofi-Aventis. Budget \$ 221,000
11. HSPPO # 01.0486: A Phase II Study of Cyclophosphamide, Etoposide, and Estramustine in Metastatic Androgen-Independent Prostate Cancer.
Principal Investigator. 2001-2010
Investigator initiated.
12. HSPPO # 04.0289: Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Cancer.
Principal Investigator. 2004-2008
Sponsor: Sanofi-Aventis. Budget \$ 277,000

CONTINUED

13. HSPPO # 02.0559: Phase I Study of Capecitabine, Temozolomide and Thalidomide in the Treatment of Advanced Solid Tumors.
Principal Investigator. 2002-2010
Investigator initiated.
14. HSPPO # 05.0591: A retrospective study of cancer patients.
Principal Investigator. 2005-2010
Investigator initiated.
15. HSPPO # 07.0369: Markers of Thrombosis in Patients with Cancer Treated with Systemic Therapy.
Principal Investigator. 2005-2010
Investigator initiated.
16. HSPPO # 08.0350: A Phase II, Open Label, Single-Arm Study of AS1411 in Patients with Metastatic Renal Cell Carcinoma.
Principal Investigator at UofL. 2008-2010
Sponsor: Antisoma, Inc. Budget \$ 500,000
17. HSPPO # 07.0297: (ECOG 2805) ASSURE. A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients with Resected Renal Cell Carcinoma..
Principal Investigator at UofL. 2007-2010
Sponsor: University of Michigan. Budget \$ 8,750
18. HSPPO # 07.0172: (3066K1-404-WW) A Randomized Trial of temsirolimus versus Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy.
Principal Investigator at UofL. 2007-2010
Sponsor: Wyeth Pharmaceuticals, Inc. Budget \$ 219,095
19. HSPPO # 07.0220: H3E-MC-JMHR: A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer.
Principal Investigator at UofL. 2007-2010
Sponsor: Lilly Research Laboratories. Budget \$ 86,562

CONTINUED

20. HSPPO # 08.0324: (3066K1-3311-WW) Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin) + Temsirolimus (Torisel) vs Bevacizumab (Avastin) + Interferon-Alfa (Roferon) as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma.
Principal Investigator at UofL. 2008-2010
Sponsor: Wyeth Pharmaceuticals, Inc. Budget \$ 280,075

21. HSPPO # 08.0535 - VEG108844: A Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma.
Principal Investigator at UofL. 2008-2010
Sponsor: Glaxo Smith Kline. Budget \$ 197,459

22. HSPPO # 08.0509.: A randomized placebo-controlled trial of the efficacy and tolerability of flexibly dosed pregabalin in the treatment of cancer-induced bone pain.
Principal Investigator at UofL. 2008-2010
Sponsor: Pfizer. Budget \$ 25,000

23. HSPPO # 09.0144: E3805 – CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer.
Principal Investigator at UofL. 2009-2010
Sponsor: ECOG. Budget \$ 20,000

24. HSPPO # 09.0067: CALGB 90203: A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-risk, Clinically Localized Prostate Cancer.
Principal Investigator at UofL. 2009-2010
Sponsor: SWOG. Budget \$ 20,000

25. HSPPO # 09.0066.: S0421: Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer.
Principal Investigator at UofL. 2009-2010
Sponsor: SWOG. Budget \$ 50,000

26. HSPPO # CRAD001L2202 An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.
Principal Investigator at UofL. 2009-2010
Sponsor: Novartis. Budget \$ 182,914

CONTINUED

27. HSPPO # Incyte - INCB 18424-351 JAK2 - A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera- Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF).
Principal Investigator at UofL. 2009-2010
Sponsor: Incyte. Budget \$ 89,242
28. HSPPO # 07.0359: 20050236-BB-IND-8362: A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as 1st-Line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer and Cross-over Second-Line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy.
Principal Investigator at UofL. 2007-2009
Sponsor: Amgen. Budget \$ 82,500
29. HSPPO # 07.0333: 20062088-105: Phase 2, Single Arm, Open-Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum-refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.
Principal Investigator at UofL. 2007-2009
Sponsor: Amgen. Budget \$ 46,699
30. HSPPO # .: CRAD001L2401: An open-level, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who are intolerant of or have progressed despite any available vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
Principal Investigator at UofL. 2009
Sponsor: Novartis Pharmaceuticals.
31. HSPPO # 08.0013: G-0034: A Phase 3 Randomized, Open-Label Study of Docetaxel in Combination with CG1940 and CG8711 versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain.
Principal Investigator at UofL. 2008
Sponsor: Cell Genesys, Inc. Budget \$ 75,545
32. HSPPO # 06.0472: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid in the Treatment of Bone Metastases in Hormone-Refractory Prostate Cancer.
Principal Investigator at UofL. 2006-2008
Sponsor: Amgen. Budget \$ 78,800

CONTINUED

33. HSPPO # 130.07: CA183002-A Multicenter, Randomized Double-Blinded Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive Cisplatin-Based Therapy (VINCENT).
Principal Investigator at UofL. 2006-2007
Sponsor: BMS. Budget \$ 72,025
34. HSPPO # 321-05: CA183001—A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium.
Principal Investigator at UofL. 2005-2007
Sponsor: BMS. Budget \$ 41,445.00
35. HSPPO # 165-06, S0431 Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Carcinoma.
Principal Investigator at UofL. 2006-2007
Sponsor: SWOG. Budget \$ 15,000
36. HSPPO # 746-01 Protocol B9E-US-S188: Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd Line Patients.
Principal Investigator at UofL. 2001-2005
Sponsor: Eli Lilly and Company. Budget \$ 48,000
37. HSPPO # 352-05: Open Label, Non-Comparative Treatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma.
Principal Investigator at UofL. 2005-2006
Sponsor: Pharmanet, Inc. Budget \$ 30,000
38. HSPPO # 336-03: Three Arm Randomized Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First Line Poor-Prognosis Subjects with Advanced Renal Cell Carcinoma.
Principal Investigator at UofL. 2003-2005
Sponsor: Wyeth. Budget \$ 120,600
39. HSPPO # 593-04 TLK 286.3020: Randomized Study of TLK286 (Telcyta) versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Principal Investigator at UofL. 2004-2005
Sponsor: Telik. Budget \$ 39,500

CONTINUED

40. HSPPO # 568.04, B9E-US-337: A Research Study of Avastin plus Gemcitabine plus 5-Fluorouracil and Leucovorin (same as A + FFG) compared to Avastin plus Oxaliplatin and 5-Fluorouracil and Leucovorin (same as A + FOLFOX 4) as Patients with Metastatic Colorectal Cancer.
Principal Investigator at UofL. 2004-2005
Sponsor: Lilly Research Laboratories. Budget \$ 25,500
41. HSPPO # 600-03: A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen, Progesterone Receptor Positive Advanced or Metastatic Breast Cancer.
Principal Investigator at UofL. 2003-2005
Sponsor: GSK. Budget \$ 118,525
42. KCI # 98-3: A Phase II Study of Docetaxel in the Treatment of Advanced Prostate Cancer Refractory to Primary Hormonal Manipulation and Anti-androgen Withdrawal.
Principal Investigator at UofL. 2001-2005
Sponsor: Aventis Pharmaceuticals Inc. Budget \$ 64,000
43. HSC # 9-02 Protocol (20010102): A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) Using Fixed Weight-Based Dosing for the Treatment of Anemia in Subjects with Non-myeloid Malignancies Receiving Multicycle Treatment.
Principal Investigator at UofL. 2002-2003
Sponsor: Amgen Inc. Budget \$ 49,550
44. HSPPO # 06.0428: A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer.
Co-Investigator. 2006-2010
Sponsors: Lilly Research Laboratories. Budget \$ 115,000
45. HSPPO # 06.0074: Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination with Pemetrexed or Pemetrexed alone, as Second-Line Treatment in Subjects with Stage IIIB/IV Non Small-Cell Lung Cancer and Progressive Disease after First-Line Treatment with a Platinum Analogue in Combination with Either Taxanes or Gemcitabine.
Co-Investigator. 2006-2010
Sponsors: EMD Pharmaceuticals, Inc. Budget \$ 45,000

CONTINUED

46. HSPPO # 00.0362: A Phase III Multi-Institutional Randomized Study of Immunization with the gp 100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 in Patients with Metastatic Melanoma.
Co-Investigator. 2001-2010
Sponsors: NCI/EPP and Chiron. Budget \$ 26,500
47. HSPPO # 04.0567, S9925: Lung Cancer Specimen Repository Protocol, Ancillary.
Co-Investigator. 2004-2010
Sponsor: Southwest Oncology Group. Budget \$ 15,000
48. HSPPO # 04.0648: Phase II Trial of Biochemotherapy (Cisplatin, Vinblastine, DTIC, plus IL-2 and Interferon) + Digoxin in Patients with Metastatic Melanoma.
Co-Investigator. 2004-2008
Investigator initiated.
49. HSPPO # 566-04, S0124: Randomized Phase III Trial of Cisplatin and Irinotecan versus cisplatin and Etoposide in Patients with Extensive Stage Small-Cell Lung Cancer.
Co-Investigator. 2004-2007
Sponsor: Southwest Oncology Group. Budget \$ 6,000
50. HSPPO # 145-06: Randomized Phase III Trial of Adjuvant vs Neo adjuvant Chemotherapy with Cisplatin and Docetaxel for Patients with Early Stage Non small Cell Lung Cancer.
Co-Investigator. 2006-2007
Sponsors: University of Pittsburgh. Budget \$ 25,000
51. HSPPO # 215-05, BAY 43-9006: Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination with Dacarbazine (DTIC) Chemotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma.
Co-Investigator. 2005-2006
Sponsor: Bayer Pharmaceuticals and Onyx Pharmaceuticals, Inc. Budget \$ 76,580
52. HSPPO # 507-04: Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women with HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer.
Co-Investigator. 2004-2005
Sponsor: Intergroup. Budget \$ 15,000

CONTINUED

53. HSPPO #, M200-1203: Phase II Open-Label Study of M200 in Combination with Dacarbazine (DTIC) in Patients with Metastatic Melanoma Not Previously Treated with Chemotherapy.
Co-Investigator. 2004-2005
Sponsor: Protein Design Labs, Inc. Budget \$ 72,476
54. HSPPO # 418-04: A Two Stage Trial of STA-4783 in Combination with Weekly Paclitaxel for Treatment of Patients with Metastatic Melanoma.
Co-Investigator. 2004-2005
Sponsor: Synta. Budget \$ 47,685
55. HSC # 568-01: Phase II Study of Temozolomide and Thalidomide in the Treatment of Advanced Melanoma.
Co-Investigator. 2001-2005
Sponsor: Schering Plough. Budget \$ 60,000
56. RTOG # 99-02: A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs. AS and RT Followed by Chemotherapy with Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer.
Co-Investigator. 2002-2004
Sponsor: RTOG. Budget \$ 30,000
57. HSC # 904-00: Nucleolin: A Novel Marker and Therapeutic Target for Lung Cancer.
Co-Investigator. 2001-2004
Sponsor: Kentucky Lung Cancer Research Fund. Budget \$150,000
58. HSC # 454-99: Early Phase Development of Tumor Markers for Improved Diagnosis and Treatments in Recently Diagnosed Breast, Lung Colon, Head and Neck, Melanoma, Ovarian and Uterine Cancer.
Co-Investigator. 2001-2004
Investigator initiated.
59. HSC # 210-01: Open Label Multi-Center Trial of Femara (letrozole) 2.5 mg as First-Line Therapy in Postmenopausal Woman with Metastatic Breast Cancer Relapsing following Adjuvant Tamoxifen Therapy.
Co-Investigator. 2001-2004
Sponsor: Novartis Pharmaceuticals Corp. Budget \$ 20,000

CONTINUED

60. HSC # 568-02, SWOG 0008: Phase III Trial of High-Dose Interferon Alpha-2b vs. Cisplatin, Vinblastine, DTIC plus IL-2 and Interferon in Patients with High-Risk Melanoma.
Co-Investigator. 2002-2003
Sponsor: SWOG. Budget \$ 8,450
61. HSPPO #, S0341: Phase II Trial of OSI-774 (NSC-718781) in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status of 2.
Co-Investigator. 2001-2003
Sponsor: Southwest Oncology Group. Budget \$ 10,000
62. HSC # 361-01: Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A versus No Adjuvant Therapy Following Resection for Stage II (Modified Astler-Coller B2) Adenocarcinoma of the Colon.
Co-Investigator. 2001-2003
Sponsor: NCI. Budget \$ 25,875
63. HSC # 630-00: A Prospective, Randomized, Open-Label Phase III Trial of Chemotherapy with Carboplatin and Paclitaxel, versus Carboplatin and Paclitaxel in combination with ISIS 3521, an Anti-sense Inhibitor of Protein Kinase C Alpha, in Patients with Advanced, Previously Untreated Non-Small Cell Lung Cancer.
Co-Investigator. 2001-2003
Sponsor: ISIS Pharmaceuticals. Budget \$ 60,000
64. HSC # 471-00: Randomized Study of Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) in Patients with Advanced Malignant Melanoma.
Co-Investigator. 2001-2003
Sponsor: Genta Incorporated. Budget \$ 63,450
65. HSC # 13-00: A Multicenter Study of NeoAdjuvant CVD/IL-2/IFN in Patients with Stage III Malignant Melanoma.
Co-Investigator. 2001-2003
Sponsor: Chiron Corporation and Schering Corporation. Budget \$ 17,500
66. HSC # 861-00: A Multi-Center, Open-Label, Randomized, Two-Arm Trial of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma.
Co-Investigator. 2001-2002
Sponsor: Sanofi-Synthelabo Inc. Budget \$ 120,000

CONTINUED

Damian A. Laber, M.D., F.A.C.P.

Page 44

67. HSC # 142-01: A Multi-Center, Open-Label, Randomized, Three-Arm Study of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) or Oxaliplatin or a Combination of 5-FU/LV + Oxaliplatin as Second-Line Treatment of Metastatic Colorectal Carcinoma.

Co-Investigator.

2001-2002

Sponsor: Sanofi-Synthelabo Inc. Budget \$ 120,000